N-glycans of human Fcγ receptor III (FcγR III)
Introduction
Receptors for the Fc portion of IgG (FcγR) are a heterogeneous family of transmembrane glycoproteins that mediate a variety of effector and regulatory functions in hematopoietic cells.
In mice and humans, three classes of FcγRs-FcγRI, FcγRII, and FcγRIII-have been described (Fridman et al., 1992; Hulett and Hogarth, 1994) . FcγRI has high affinity for monomeric IgG, whereas FcγRII and FcγRIII exhibit low affinity for monomeric IgG but bind IgG-containing immune complexes with high avidity. FcγRII and FcγRIII possess similar extracellular regions composed of two Ig-like domains. There exist a variety of isoforms of the individual classes of FcγRs (Fridman et al., 1993) . For example, isoforms for human FcγRIII are transmembrane FcγRIIIa and glycosylphosphatidylinositol (GPI)-linked FcγRIIIb, coded by two separate genes. Some of those isoforms are expressed as soluble form (sFcγR) that consist of their extracellular domains produced by proteolytic cleavage (Huizinga et al., 1990; Sautès et al., 1991) .
Human FcγRIIIb and its soluble counterpart interact not only with IgG but also with cell surface receptors, such as complement receptor type 3 (CR3; CD11b/CD18) Galon et al., 1996) . It has been reported that the glycosylation of (s)FcγRIII is involved in its interactions with classical (IgG) and nonclassical (CR3) ligands. Glycosylation of sFcγRIII plays an inhibitory role in the interaction with human IgG3 but not IgG1 (Galon et al., 1997; van den Nieuwenhof et al., 2000) . On the other hand, the interaction with CR3 is mediated by carbohydrate moieties expressed on (s)FcγRIII molecules (Sehgal et al., 1993; Galon et al., 1996) . Although structural basis of the interactions between IgG and FcγRs has been provided by nuclear magnetic resonance spectroscopy (Kato et al., 2000) and X-ray crystallography (Sondermann et al., 2000; Radaev et al., 2001 ) by use of recombinant sFcγRs, the role of FcγRIII glycosylation in its binding of ligands has not been fully elucidated from structural aspects.
Therefore, to gain deeper insights into this question, human sFcγRIII expressed by an appropriate mammalian expression system are required. Expression systems to produce high amounts of recombinant sFcγRs of eukariotic cell lines have been developed (Teillaud et al., 1994; Sautès et al., 1994) . We have shown that recombinant human sFcγRIII (rhsFcγRIII), which is produced in baby hamster kidney (BHK) cells, conserve the ability to interact with CR3, which is comparable to that of native sFcγRIII purified from human serum (Galon et al., 1996) . This strongly indicates that rhsFcγRIII and the native sFcγRIII glycoproteins carry common glycan structure(s) essential for interaction with CR3.
Here we report the N-glycosylation profile of rhsFcγRIII produced in BHK cells. By use of a 3D high-performance liquid chromatography (HPLC) mapping technique (Takahashi et al., 1995a Tomiya et al., 1988) , structures of N-glycans expressed on rhsFcγRIII have been determined throughout, discriminating possible isomers resulting from partial galactosylation and sialylation. The N-glycosylation profile thus obtained has been compared with that of recombinant mouse sFcγRII (rmsFcγRII) produced in BHK cells. Similarity and difference of the N-glycosylation profiles between rhsFcγRIII and rmsFcγRII are discussed in light of their function.
Results

Separation of N-glycans by three successive HPLC steps
The pyridylamine (PA)-glycans released from sFcγRIII were separated into neutral (N), monosialyl (MS), disialyl (DS), trisialyl (TS), and tetrasialyl (TeS) oligosaccharide fractions by DEAE-5PW column (first HPLC) ( Figure 1A ). All ionic charges in the sFcγRIII could be attributable to α-sialic acids, because all acidic fractions changed to neutral species after Arthrobacter α-sialidase digestion (data not shown).
Each of these fractions were applied to the octadecylsilica (ODS) column, using exactly the same chromatographic conditions for neutral and all sialylated derivatives ( Figure 1B) . The resulting fractions were numbered in order of elution time, that is, N10, MS1, or DS3. Each of the PA-labeled fractions thus coded was further fractionated by molecular size using the amide-silica column. The fractions separated on the amide-silica columns were alphabetically coded in order of elution time. N8 fraction was separated into N8a and N8b; N10 into N10a, N10b, and N10c; N11 into N11a, N11b, and N11c; and the monosialyl fraction MS3 into MS3a and MS3b. Other ODS fractions appeared as single peaks on amide-silica column (data not shown). Although disialyl DS5 could still not be resolved on this step, it contains two components that were unambiguously differentiated only after digestion with β-galactosidase and β-N-acetylhexosaminidase.
Identification of N-glycan structures
Structural assignment of all neutral and sialyl N-glycans from sFcγRIII was performed by 2D mapping technique, as described elsewhere (Takahashi et al., 1995a) . Except for six compounds (monosialyl MS1, MS4, and MS5 and disialyl DS2, DS3, and DS5), coordinates of all N-glycans from sFcγRIII coincided with those of known N-glycans on the map. Therefore, they were tentatively assigned to the known N-glycans as shown in Table I . Then, cochromatography on ODS and amide-silica columns of each of the sample PA-glycans with the corresponding reference compound confirmed those assignments. The coordinate sets of six compounds (monosialyl MS1, MS4, and MS5; disialyl DS2, DS3, and DS5) do not match, by direct comparison, with any of the reference compounds available on the 2D map accumulated prior to this study.
Determination of novel sialyl N-glycan structures
It has been established that deciphering the α(2,6)-versus α(2,3)-sialylation can be made by the differential glucose unit (GU) changes of on the amide-silica column (Takahashi et al., 1995a,b) . After sialidase digestion, its GU value on the amide-silica column increases by about 0.4/residue of Neu5Ac if Neu5Ac is α(2,3)-linked, but little change is observed for Neu5Acα(2,6). Because GU changes on the amide-silica column on the sialidase treatment of the N-glycans from sFcγRIII were approximately + 0.4/residue of Neu5Ac, we concluded that all the Neu5Ac are α(2,3)-linked in this glycoprotein. After sialidase digestion, MS1 released sialic acid and changed into the known neutral triantennary compound 310.18, whereas MS4 as well as MS5 were converted into the known neutral tetraantennary compound 410.16 (Figure 2 ). To determine which branch was terminated with an α(2,3)-sialic acid residue, intact MS1, MS4, and MS5 were digested with β-galactosidase and then with β-N-acetylhexosaminidase. Because MS1 was expected to change into a monosialyl monoantennary compound on the 2D map, the resultant coordinates should coincide with one of the three possible references found in Figure 2B . candidates. On the basis of these data, we conclude that the position of sialylation in MS1 is at the Galβ4GlcNAcβ2Manα3 branch.
Similarly, the resultant compounds from the β-galactosidase and β-N-acetylhexosaminidase digestion of MS4 and MS5 were expected to be one of the following four monosialyl monoantennary compounds: 1A2-110.8, 1A2-110.4, 1A2-110.3, and 1A2-110.9 found in Figure 2B .
On the enzymatic treatments, the coordinates of MS4 and MS5 changed from (15.2, 9.7) and (15.6, 9.7) to (11.8, 5.6) and (14.3, 5.5), respectively (Figure 2) . The strongest candidates among the four possible aforementioned structures were 1A2-110.4 (11.8, 5.6) for the digested MS4, and 1A2-110.3 (14.2, 5.5) for the digested MS5. By cochromatography, we confirmed that the digestion products of MS4 and MS5 are identical with 1A2-110.4 and 1A2-110.3, respectively, among the four possible candidates. On the basis of these data we conclude that the position of sialylation in these compounds, specifically, Galβ4GlcNAcβ2Manα3 branch in MS4 and Galβ4GlcNAcβ2Manα6 branch in MS5. The structures of MS1, MS4, MS5 thus identified are included in Table I. DS5 was converted into the known tetraantennary reference 410.16 on releasing sialic acids. β-Galactosidase and β-N-acetylhexosaminidase digestion of DS5 gave rise to two fractions, DSx (14.5, 6.6) and DSy (16.1, 6 .6) at a molar ratio of 1:1 on the 2D map. Because any possible disialyl biantennary compounds as references were not available, the structures of DSx and Dsy could be only estimated to be that shown in Scheme 1 on the basis of GU differences computed from the contributions of each component monosaccharide unit in a specific position expressed in GU (Tomiya and Takahashi, 1998) . These results indicated that DS5 was a 1:1 mixture of two disialyl tetraantennary compounds; see Scheme 2.
In a similar way, it was revealed that DS2 and DS3, with prevalence of 0.7% and 0.6%, respectively, were disialyl tetraantennary compounds. However, because of the limited amount of the sample, the positions of the two sialic acid residues could not be unambiguously assigned. 
Discussion
In the present article, we have identified 39 major N-glycan structures of rhsFcγRIII produced in BHK cells, which consist of 20 neutral (77.6%), 7 monosialyl (15.7%), 6 disialyl (4.0%), 5 trisialyl (1.5%), and 1 tetrasialyl (1.2%) oligosaccharides. Fourteen percent of the total N-glycans is of high-mannose type. The complex-type N-glycans are fucosylated exclusively by α(1,6) linkage and lack bisecting GlcNAc. Sialylation occurs through α(2,3) but not α(2,6) linkage. All of these features are consistent with those so far reported for glycoproteins expressed by BHK cells (Tomiya et al., 1993; Nimtz et al., 1993; Takahashi et al., 1998) . GalNAc residue(s) were contained in 5.9% of the total N-glycans instead of terminal Gal residue, for example, N13 and MS6 in Table I . This type of glycosylation has been observed for other recombinant glycoproteins produced in BHK cells but has never been found in those produced in Chinese hamster ovary cells most likely due to the absence of a functional β4-GalNAc transferase (Tsuda et al., 1988) . As reported previously, urinary kallidinogenase (Tomiya et al., 1993) and human urokinase (Bergwerff et al., 1995) produced in natural human kidney have plenty of GalNAc-containing N-glycans. It is possible that production of GalNAc-containing N-glycans is characteristic for kidney(-derived) cells.
In a previous publication, we determined 18 major N-glycan structures of rmsFcγRII . Figure 3 compares the N-glycosylation profile of rhsFcγRIII determined in the present study with that of rmsFcγRII by plotting all sample coordinates on the 2D map. Much more divergent N-glycan structures are exhibited by rhsFcγRIII than by rmsFcγRII. In particular, high-mannose type N-glycans (from N1 to N5 in Table I , and Figure 3A ) are expressed only by rhsFcγRIII. Furthermore, larger multiantennary complex type oligosaccharides are predominant in the rhsFcγRIII. Indeed, for rhsFcγRIII, the most abundant glycan is a typical tetraantennary N12 (18%) and the total content of tetraantennary group (including N12) is 43%. On the contrary, most of the oligosaccharides of rmsFcγRII are biantennary N-glycans and prevalence of tetraantennary glycan is only 0.9%.
It has been reported that on human polymorphonuclear leukocytes, FcγRIII, but not FcγRII, expresses Conacavalin A binding and endoglycosidase H-sensitive oligosaccharides (Kimberly et al., 1989) . On the basis of all these data, we suggest that expression of the high-mannose type oligosaccharides is specific for human FcγRIII, and they can be at least partially reproduced in the recombinant soluble form produced by BHK cells.
The lectin-like site of CR3 has been shown to be responsible for binding to GPI-anchored FcγRIII as well as to rhsFcγRIII (Stöckl et al., 1995; Galon et al., 1996) . The lectin-like site of CR3 binds mannose-rich compounds such as zymosan (Ross et al., 1985) , and the FcγRIII-CR3 cocapping is inhibited by N-acetyl-D-glucosamine, α-methyl-D-mannoside, and D-mannose, but not by glucose, galactose, N-acetyl-neuraminic acid, fucose, sorbitol, fructose, nor sucrose (Yamamoto et al., 1989) . Inhibitory effects by α-or β-methyl-D-mannoside have been observed for the rhsFcγRIII-CR3 interaction (Galon et al., 1996) . One intriguing possibility is that the interaction of CR3 with FcγRIIIb involves the lectin-like region of CD11b and the high-mannose type oligosaccharide(s) characteristically exhibited by FcγRIII. The human sFcγRIII used in the present study possesses six possible N-glycosylation sites (positions 37, 44, 63, 73, 162, and 169) , whereas mouse sFcγRII has four sites (positions 36, 63, 138, and 145) . Thus most of the glycosylation sites are not conserved, although these two glycoproteins share 50% amino acid identity with each other. We suggest that the local environment (e.g., local conformational factors) surrounding the individual glycosylation sites affect the processing of the expressed glycans, resulting in differential overall glycosylation profiles between the two glycoproteins with close structural similarlity of polypeptide chains. If this is true, it is quite likely that different glycosylation sites in human FcγRIII molecules exhibit different N-glycosylation profiles. Analyses of site-specific glycosylations of the recombinant human FcγRIII is under way in our laboratory.
Materials and methods
Enzymes
Glycoamidase A (also known as glycopeptidase A) from sweet almond (Takahashi, 1977) , β-galactosidase and β-N-acetylhexosaminidase from jack bean were purchased from Seikagaku Kogyo (Tokyo). Sialidase from Arthrobacter ureafaciens was obtained from Nacalai Tesque (Kyoto, Japan). Trypsin, chymotrypsin, and pronase were from Sigma (St. Louis, MO).
Reference N-glycans
The PA-derivatives of isomalto-oligosaccharides (4-20 glucose residues) and of reference N-glycans (code numbers, M5.1, M6.1, M8.2, 110.1, 110.3, 210.1, 210.2, 210.3, 210.4, 310.8, 410.9, 410.12, 410.13, and 410.16) The following PA-glycans were prepared by known methods: M6.10 and M7.7 were obtained from M9.1 by jack bean α-mannosidase digestion (Tomiya et al., 1991) ; 410.42 was prepared from recombinant erythropoietin (Tomiya et al., 1993) ; 410.15 was from 3A5-410.16 by β-galactosidase then sialidase digestion; 210.4b, 1A2-210.3, 1A3-210.4, 1A4-210.4, 1A2-210.4a1, 2A4-210.4, 3A2-310.18, 3A3-410.16, 3A5-410.16, 3A6-410.16, and 4A2-410.16 were from mouse sFcγRII and 310.18, 2A3-310.18 and 3A4-410.16 were from human integrin (Nakagawa et al., 1996) . . The glycans whose prevalence is more and less than 3% are represented with larger and smaller circles, respectively.
Preparation of sFcγRIII
The cDNA encoding the NA2 form of human FcγRIII-B ectodomains (194-amino-acid-long including a 7-amino-acid C-terminal stop linker) was expressed in the BHK cell line. The rhsFcγRIII glycoprotein was purified by ion exchange and affinity chromatography as described (Sautès et al., 1994) . Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis showed that the material was 99% pure and migrated with apparent molecular mass 47 to 56 kDa.
Preparation of PA N-glycans from sFcγRIII and analysis by 3D HPLC mapping technique
One milligram of rhsFcγRIII was used as starting material. Experimental procedures of liberation and PA-derivatization of N-glycans and chromatographic conditions have been described in detail elsewhere (Nakagawa et al., 1995; Takahashi et al., 1995a) . Briefly, sFcγRIII was proteolyzed with trypsin and chymotrypsin mixture. The proteolysate was further digested with glycoamidase A to liberate N-glycans. After removing the peptidic materials, the reducing ends of N-glycans were reductively aminated with a fluorescent reagent, 2-aminopyridine using sodium cyanoborohydride (Yamamoto et al., 2001) .
The mixture of PA-oligosaccharides was separated by HPLC on a diethylaminoethyl (DEAE) column according to the sialic acid content. Each separated fraction was then applied to an ODS HPLC column. Then each of the fraction separated on the ODS column was applied to the amide-silica column for the separation on the basis of their sizes. The elution times of a given PA-oligosaccharides on ODS and amide-silica columns, both of which are calibrated in GUs, provide a unique set of coordinates on the 2D map. The coordinates of the PA-glycans originating from sFcγRIII were compared with those of the authentic reference compounds.
The GUs of all unknown N-glycans were first compared with those of the reference N-glycans on the 2D map. We then select a few references from the data as candidates whose coordinates coincided with those of the sample within allowable error (± 5%). The sample PA-glycan and each of the selected references were coinjected onto ODS and amide-silica columns. Identification was made judging whether they are eluted simultaneously giving a single peak on both HPLC profiles.
For further confirmation, the sample PA-glycan was digested with one or more exoglycosidases. At each step of the trimming, the elution positions of the resultant PA-glycans were examined as to whether they could be identified with the expected reference compound. The trimming and comparison was continued until the product from the sample compound became coincidental with a reference PA-oligosaccharide on the map.
Each PA-glycan (approximately 50 pmol) isolated on the ODS and amide-silica columns was digested by exoglycosidases (α-sialidase from A. ureafaciens, β-galactosidase and β-N-acetylhexosaminidase from jack bean under the conditions described elsewhere; Nakagawa et al., 1995) .
